Loading
NASDAQHealthcareBiotechnology
Latest quote
$56.20
+$1.58 · +2.89%
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Regular session
$56.20
+$1.58 · +2.89%
Regular session · ET · Market data may be delayed.
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Day range
Current $56.20
52-week range
Current $56.20
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
30
Expensive
Sentiment
60
Mixed
Risk
29
Moderate Risk
Momentum
68
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Day range
Current $56.20
52-week range
Current $56.20
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 33.19M USD | 18.82M USD |
| Cost of goods sold | 208.44M USD | 1.94M USD | 2.84M USD | 123.04M USD | 108.47M USD |
| Gross profit | −208.44M USD | −1.94M USD | −2.84M USD | −89.85M USD | −89.65M USD |
| Research and development | 208.44M USD | 182.61M USD | 119.06M USD | 124.44M USD | 108.47M USD |
| Selling, general, and administrative | 176.21M USD | 67.5M USD | 49.4M USD | 42.62M USD | 40.27M USD |
| Operating expenses | 176.21M USD | 250.12M USD | 168.45M USD | 44.52M USD | 40.27M USD |
| Interest income | 13.9M USD | 12.68M USD | — | — | — |
| Interest expense | 6.89M USD | 6.84M USD | — | — | — |
| Depreciation and amortization | 1.66M USD | 1.94M USD | 2.84M USD | 2.99M USD | 2.63M USD |
| Operating income | −384.65M USD | −252.05M USD | −171.3M USD | −134.37M USD | −129.92M USD |
| Net income | −377.94M USD | −246.29M USD | −165.79M USD | −134.5M USD | −131.8M USD |
Company facts updated Sep 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI162.7M0.01%2.3T USD0.03%$373.48-0.55%
iShares Russell 2000 ETFIWM155.15M0.20%80.51B USD0.19%$288.23-0.83%
State Street SPDR S&P Biotech ETFXBI133.56M1.18%11.33B USD0.35%$156.87-1.58%
Vanguard Extended Market ETFVXF54.18M0.06%93.7B USD0.05%$237.07-0.67%
iShares Russell 2000 Growth ETFIWO53.98M0.37%14.7B USD0.24%$367.24-1.00%
iShares Biotechnology ETFIBB40.18M0.38%10.73B USD0.44%$202.74-1.34%
Vanguard Russell 2000 ETFVTWO29.67M0.17%17.4B USD0.06%$116.54-0.83%
Schwab U.S. Small-Cap ETFSCHA25.87M0.11%22.62B USD0.03%$33.725-1.10%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
